Skip to content

SPAC Feed

Curated SPACs News

  • News
  • Opinions
  • Events
  • Videos
  • Resources
  • Contact Us
  • News
Posted on March 13, 2023

Moody's affirms Pfizer's A1 rating; revises outlook to negative – Moody's

Moody’s affirms Pfizer’s A1 rating; revises outlook to negative  Moody’s
Source: Moody’s affirms Pfizer’s A1 rating; revises outlook to negative – Moody’s

By sf-admin

Post navigation

S-1 – cbdMD, Inc. (0001644903) (Filer)
ASPAC II ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) – Marketscreener.com


  • About Us
  • Contact Us
  • Subscribe
Copyright © 2026 SPAC Feed. All Rights Reserved | News Vibe by Theme Palace